Dendright-Janssen deal receives industry awards from two different competitions

September 22, 2014

Dendright is very pleased to announce that last week it received two awards for outstanding research and commercialisation endeavours pertaining to its liposome-based therapy for rheumatoid arthritis, from industry body Knowledge Commercialisation Australia (KCA) as well as from The University of Queensland (UQ).

At KCA’s inaugural Research Commercialisation Awards, Dendright/UniQuest won the Best Commercial Deal category for its 2013 Research and Option to License Agreement with Janssen Biotech Inc. for its immunotherapy technology related to the treatment of rheumatoid arthritis. 

UniQuest Pty Ltd is the main commercialisation company for The University of Queensland and Dendright Pty Ltd is a wholly owned start-up company of UniQuest.

Dendright CEO, Helen Roberts commented “it is very rewarding for the Dendright/UniQuest and Janssen teams to be recognised in this way. 

The innovative nature of the deal structure and the opportunity it brings Dendright to partner with one of the world’s most successful pharmaceutical companies underpins a positive and strongly collaborative approach to translation of the Curcusome-RA research. 

Both parties are seeking better patient outcomes for this challenging disease and research commercialization success will deliver meaningful benefit to patients, their careers and the broader Australian community”.  

Professor Ranjeny Thomas from The University of Queensland, whose research underpins the liposome-based therapy for rheumatoid arthritis was separately recognized at UQ’s Partners in Research Excellence Awards with Janssen represented by Ms. Kathy Connell, Director New Ventures - ANZ, Asia Pacific Innovation Centre. 

The Partners in Research Excellence Award recognizes industry partnerships as a critical success factor enabling academic research to move from the research bench to the marketplace.

Dendright and its innovative partnership with Janssen was recognized for its potential to bring a transformational healthcare solution to patients suffering rheumatoid arthritis.

Media Enquiries:

Helen Roberts, CEO, +61 (0) 419 657504, helen.roberts@dendright.com.au 

About Dendright Pty Ltd

Dendright Pty Ltd was established in 2005 and assisted by grants from the Queensland Government’s Innovation Start-up Scheme and the Australian Government’s Biotechnology Innovation Fund so that Professor Ranjeny Thomas and her team could focus on finding a way for the body’s own immune system to “re-educate” the cells that cause autoimmune diseases. Professor Thomas’ research at the University of Queensland Diamantina Institute has also been supported by Arthritis Queensland, a peak community organisation, the Australian Research Council and Australia’s National Health and Medical Research Council.

In addition to the RA therapy in preclinical development, the Dendright platform technology is being used to develop new therapies for type 1 diabetes.

Share This